ACRX - AcelRx Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.75
0.00 (0.00%)
At close: 4:00PM EDT

1.75 0.00 (0.00%)
After hours: 4:28PM EDT

Stock chart is not supported by your current browser
Previous Close1.75
Open1.75
Bid1.70 x 16400
Ask1.75 x 4900
Day's Range1.55 - 1.80
52 Week Range1.55 - 5.75
Volume3,226,499
Avg. Volume2,215,598
Market Cap79.42M
Beta3.14
PE Ratio (TTM)-1.60
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • AcelRx's Opioid Painkiller Dsuvia Gets CRL, Shares Plunge
    Zacks6 days ago

    AcelRx's Opioid Painkiller Dsuvia Gets CRL, Shares Plunge

    AcelRx (ACRX) receives CRL for its opioid painkiller, Dusvia. The FDA has requested resubmission with additional safety data and recommended changes to drug administration.

  • Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback
    Zacks6 days ago

    Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback

    Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.

  • GuruFocus.com7 days ago

    CarGurus Gains Nearly 80% in 1st Day of Trading

    AcelRx, Blackhawk Network and Juniper Networks fall

  • Reuters7 days ago

    AcelRx Pharma shares sink as FDA rejects opioid painkiller

    Shares of AcelRx Pharmaceuticals Inc plunged more than 60 percent on Thursday after the U.S. Food and Drug Administration declined to approve its opioid painkiller Dsuvia. There were more than 33,000 deaths in the United States in 2015 related to the abuse of the family of heavy-duty painkillers, and the resulting outcry has made the FDA extremely cautious about issuing new approvals. The FDA last month rejected another opioid painkiller made by Intellipharmaceutics International Inc , asking for more proof of the drug's ability to prevent abuse.

  • Why AcelRx Pharmaceuticals Inc Got Cut in Half Today
    Motley Fool7 days ago

    Why AcelRx Pharmaceuticals Inc Got Cut in Half Today

    An FDA rejection sends shares of the drugmaker lower.

  • MarketWatch7 days ago

    AcelRx's stock plunges toward record low after FDA's complete response letter

    Shares of AcelRx Pharmaceuticals Inc. plunged 69% in premarket trade Thursday, after the Food and Drug Administration said it could not approve the new drug application of AcelRx's pain treatment Dsuvia ...

  • Reuters7 days ago

    FDA rejects AcelRx Pharma's pain drug

    U.S. health regulators did not approve AcelRx Pharmaceuticals Inc's drug Dsuvia in its present form for the management of acute pain in trauma and ambulatory settings, the company said on Thursday. The ...

  • Capital Cube16 days ago

    ETFs with exposure to AcelRx Pharmaceuticals, Inc. : October 3, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AcelRx Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ACRX-US. Comparing the performance and risk of AcelRx Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • AcelRx Pharmaceuticals (ACRX) in Focus: Stock Moves 19.6% Higher
    Zacks16 days ago

    AcelRx Pharmaceuticals (ACRX) in Focus: Stock Moves 19.6% Higher

    AcelRx Pharmaceuticalssaw its shares rise nearly 20% on the day in anticipation of an FDA approval for AcelRx's pain medication Dsuvia.

  • Why AcelRx Pharmaceuticals Inc Jumped Higher Today
    Motley Fool17 days ago

    Why AcelRx Pharmaceuticals Inc Jumped Higher Today

    Investors are buying ahead of an upcoming binary event.

  • Should You Have AcelRx Pharmaceuticals Inc’s (ACRX) In Your Portfolio?
    Simply Wall St.20 days ago

    Should You Have AcelRx Pharmaceuticals Inc’s (ACRX) In Your Portfolio?

    If you are a shareholder in AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • Implied Volatility Surging for AcelRx Pharmaceuticals (ACRX) Stock Options
    Zacks23 days ago

    Implied Volatility Surging for AcelRx Pharmaceuticals (ACRX) Stock Options

    Investors need to pay close attention to AcelRx Pharmaceuticals (ACRX) stock based on the movements in the options market lately.

  • Capital Cube27 days ago

    ETFs with exposure to AcelRx Pharmaceuticals, Inc. : September 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AcelRx Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ACRX-US. Comparing the performance and risk of AcelRx Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cubelast month

    ETFs with exposure to AcelRx Pharmaceuticals, Inc. : September 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AcelRx Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ACRX-US. Comparing the performance and risk of AcelRx Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube2 months ago

    ETFs with exposure to AcelRx Pharmaceuticals, Inc. : August 31, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AcelRx Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ACRX-US. Comparing the performance and risk of AcelRx Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
    Capital Cube2 months ago

    AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017

    Categories: Yahoo FinanceGet free summary analysis AcelRx Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of AcelRx Pharmaceuticals, Inc. – Pain Therapeutics, Inc., BioDelivery Sciences International, Inc., DURECT Corporation, Insys Therapeutics, Inc., Galena Biopharma, Inc., Cara Therapeutics Inc and Medicines Company (PTIE-US, BDSI-US, DRRX-US, ... Read more (Read more...)

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ACRX earnings conference call or presentation 1-Aug-17 12:30pm GMT

    Q2 2017 AcelRx Pharmaceuticals Inc Earnings Call

  • SmarterAnalyst3 months ago

    AcelRx Pharmaceuticals Inc (ACRX) Could Face Opioid Heat from FDA with Zalviso, Worries Roth Capital

    Roth Capital Michael Higgins believes this does not bode well for ACRX even in the wake of EU post-approval, concerned that 14 months following the FDA issuing its CRL, "[...] the FDA's heightened sensitivity to the opioid crisis is likely to prevent Zalviso’s approval." In fact, Higgings anticipates "today's FDA may have a problem" here, and asserts that this "overshadowed" earnings. "With FDA skating on thin ice, in our view, we believe Zalviso's NDA as too heavy for the agency to bear," contends Higgins, elaborating, "In our modeling we have dropped our probability of Zalviso’s U.S. approval from 25% to 0%. "We believe Zalviso's 2015 CRL has been anchoring a cloud over ACRX shares, as investor attention on Dsuvia has been slow to develop," surmises the analyst.

  • Associated Press3 months ago

    AcelRx Pharmaceuticals reports 2Q loss

    On a per-share basis, the Redwood City, California-based company said it had a loss of 29 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...

  • Capital Cube3 months ago

    ETFs with exposure to AcelRx Pharmaceuticals, Inc. : July 31, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AcelRx Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ACRX-US. Comparing the performance and risk of AcelRx Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • SmarterAnalyst3 months ago

    Jefferies Sees Strong Upside in AcelRx Pharmaceuticals’ Shares and Set a $7 Price Target

    In a research report issued Friday, Jefferies analyst Matthew Andrews assumed coverage on shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), with a Buy rating and a $7.00 price target, which implies an upside of 208% from current levels. "While the FDA under Dr. Gottlieb is focused on addressing the U.S.’s opioid crisis, we believe this will largely focus on the appropriate use and duration of chronic (not acute) opioid therapy. The analyst concluded, "ACRX is under-valued due to potent oral opioid Dsuvia's promise in medicallysupervised acute pain markets (~92M patients) and we see high likelihood of U.S./EU approvals in Q4'17/H1'18.

  • Capital Cube3 months ago

    ETFs with exposure to AcelRx Pharmaceuticals, Inc. : July 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AcelRx Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ACRX-US. Comparing the performance and risk of AcelRx Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube4 months ago

    ETFs with exposure to AcelRx Pharmaceuticals, Inc. : June 30, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AcelRx Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ACRX-US. Comparing the performance and risk of AcelRx Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • 5 Biotech Stocks With Major Catalysts in July
    Motley Fool4 months ago

    5 Biotech Stocks With Major Catalysts in July

    Big news is on the way soon for AcelRx, Alnylam, Amgen, Dynavax, and Merck.

  • Capital Cube4 months ago

    ETFs with exposure to AcelRx Pharmaceuticals, Inc. : June 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AcelRx Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ACRX-US. Comparing the performance and risk of AcelRx Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)